Abbvie Inc (ABBV) Ordinary Shares USD 0.01

Sell:$202.13Buy:$202.14$1.20 (0.60%)

Prices delayed by at least 15 minutes
Sell:$202.13
Buy:$202.14
Change:$1.20 (0.60%)
Deal now
Prices delayed by at least 15 minutes
Sell:$202.13
Buy:$202.14
Change:$1.20 (0.60%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.

Key people

Richard A. Gonzalez
Executive Chairman of the Board
Robert A. Michael
Chairman of the Board, Chief Executive Officer
Scott T. Reents
Chief Financial Officer, Executive Vice President
Timothy J. Richmond
Chief Human Resources Officer, Executive Vice President
Roopal Thakkar
Executive Vice President - Research & Development, Chief Scientific Officer
Perry C. Siatis
Executive Vice President, General Counsel, Secretary
Nicholas J. Donoghoe
Executive Vice President, Chief Business and Strategy Officer
Azita Saleki-Gerhardt
Executive Vice President, Chief Operations Officer
Jeffrey R. Stewart
Executive Vice President, Chief Commercial Officer
Kevin K. Buckbee
Senior Vice President, Controller
Roxanne S. Austin
Lead Independent Director
Robert J. Alpern
Independent Director
William H. L. Burnside
Independent Director
Jennifer L. Davis
Independent Director
Thomas C. Freyman
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US00287Y1091
  • Market cap
    $348.39bn
  • Employees
    55,000
  • Shares in issue
    1.83bn
  • Exchange
    New York Stock Exchange
  • Index
    S&P 500, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.